Raymond James Financial
EWTX icon

Raymond James Financial’s Edgewise Therapeutics EWTX Stock Holding History

Raymond James Financial’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$620K Sell
19,678
-1,931
-9% -$55.7K ﹤0.01% 4206
2025
Q4 		$536K Buy
21,609
+8,230
+62% +$165K ﹤0.01% 4222
2025
Q3 		$217K Buy
13,379
+11,821
+759% +$168K ﹤0.01% 4589
2025
Q2 		$20.4K Buy
+1,558
New +$22.5K ﹤0.01% 5590

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Raymond James Financial's EWTX Position: Q1 2026 in Review

Raymond James Financial reduced its Edgewise Therapeutics (EWTX) stake by 8.9% in Q1 2026, selling an estimated $55.7K and leaving 19,678 shares worth $620K. The position accounts for ﹤0.01% of the portfolio, ranked #4206.

Raymond James Financial first reported a position in EWTX in Q2 2025 and has held it in 4 quarters since. 214 funds tracked by Wall St. Rank hold EWTX as of Q1 2026.

  • Raymond James Financial held 19,678 shares of Edgewise Therapeutics worth $620K as of Q1 2026.
  • Raymond James Financial sold 1,931 Edgewise Therapeutics shares in Q1 2026, an estimated $55.7K.
  • Edgewise Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #4206 holding.
  • Raymond James Financial first reported a position in Edgewise Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 214 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.